Collectively, these results confirm that tumours treated with PI3K/mTORi and/or PI3K/mTORi+PD‐1i are enriched for an actively proliferating cytotoxic CD4+ and CD8+ T‐cell population, indicative of an ongoing adaptive anti‐tumour immune response. Here, PIK3CB is linked to neoplasm.